Neurogene (NGNE) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Neurogene (NGNE) has outperformed REGENXBIO (RGNX) over the past year, losing 16.3% versus a loss of 33.7%. Over five years, RGNX leads with a -77.6% price change compared with -81.7% for NGNE. REGENXBIO is the larger company by market cap ($532.7 million vs $528.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | RGNX |
|---|---|---|
| Share price | $26.40 | $8.07 |
| Market cap | $528.30M | $532.73M |
| 1-day change | -0.38% | -0.25% |
| YTD return | +28.16% | -43.96% |
| 1-year return | -16.35% | -33.69% |
| 5-year return | -81.72% | -77.55% |
| EPS (TTM) | $-5.04 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $16.19 |
| 52-week low | $15.93 | $5.46 |
| Distance from 52-week high | -39.53% | -50.15% |
| Analyst consensus | none | buy |
| Avg. price target upside | +195.00% | +192.19% |
| Average volume | 246.44K | 1.50M |
| Shares outstanding | 20.01M | 66.01M |
| Employees | 131 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed RGNX by 17.3 percentage points over the past year.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
NGNE vs RGNX FAQ
Which is bigger, Neurogene or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $532.73M compared with $528.30M for Neurogene (NGNE).
Which stock has performed better over the past year, NGNE or RGNX?
NGNE returned -16.35% over the past 12 months, compared with -33.69% for RGNX (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Neurogene and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.